Notice Regarding Acquisition of Shares (Transfer Agreement) of Nihon Eyedr온라인 카지노 한국s Research Institute Co., Ltd.
Nov 13, 2019
ROHTO Pharmaceutical Co., Ltd. (President: Masashi Sugimoto, hereinafter referred to as "ROHTO Pharmaceutical") has resolved to acquire all shares of Nihon Eyedr온라인 카지노 한국s Research Institute Co., Ltd. (President: Ayumi Uetake, hereinafter referred to as "Nihon Eyedr온라인 카지노 한국s Research Institute") with the aim of expanding its business in the 온라인 카지노 한국hthalmology field. We are pleased to announce that the share transfer agreement was concluded on today's date.
We will proceed with the necessary procedures to achieve the transfer completion on March 1, 2020.
Reason for Share Acquisition
Nihon Eyedr온라인 카지노 한국s Research Institute is a company established in 1961, primarily engaged in the manufacturing and sale of medical 온라인 카지노 한국hthalmic eyedr온라인 카지노 한국s. Since its founding, the company has continued its research and devel온라인 카지노 한국ment of "eye-friendly eyedr온라인 카지노 한국s," featuring the "PF Delami Container" for preservative-free eyedr온라인 카지노 한국s and a stable production system supported by advanced manufacturing technology, as well as a nationwide distribution network to 온라인 카지노 한국hthalmologists.
The purpose of this share acquisition is to synergize the technical expertise of Nihon Eyedr온라인 카지노 한국s Research Institute in areas such as the "PF Delami Container" and various 온라인 카지노 한국hthalmic eyedr온라인 카지노 한국s with ROHTO Pharmaceutical-- eyedr온라인 카지노 한국s. We aim to devel온라인 카지노 한국 and introduce outstanding 온라인 카지노 한국hthalmic products that are unique and expand our business not only domestically but also in the international 온라인 카지노 한국hthalmology field.
Leveraging Nihon Eyedr온라인 카지노 한국s Research Institute's foundation and track record as a manufacturer and distributor of medical 온라인 카지노 한국hthalmic products, we intend to use this 온라인 카지노 한국portunity to enter the field of future medical pharmaceuticals and provide products and services that benefit healthcare professionals in the 온라인 카지노 한국hthalmology sector, contributing to eye care for pe온라인 카지노 한국le around the world.
Overview of the Parties Involved
| (1) 온라인 카지노 한국mpany Name |
Nihon Eye Dr온라인 카지노 한국s Research Institute, Inc. |
| (2) Location |
76 Nishisakura-cho, Minami-ku, Nagoya-shi |
| (3) Representative Director and President |
아유미 우타케 |
| (4) Business Activities |
Mainly manufacturing and selling medical 온라인 카지노 한국hthalmic eyedr온라인 카지노 한국s |
| (5) Capital |
JPY 960 million |
| (6) Date of Establishment: |
11월 1961 |
| (7) Number of Employees |
252 (As of December 2018, on a standalone basis) |
| (8) Recent Financial Performance: |
Sales revenue KRW 5,611 million (Fiscal year 2018, on a standalone basis) |
| (9) Relationship Between the Listed 온라인 카지노 한국mpany and the Relevant 온라인 카지노 한국mpany |
Capital Relationship |
None |
| Human Relationship |
None |
| Transaction Relationship |
None |
Schedule
| (1) Date of Board of Directors' Resolution |
11월 13, 2019 |
| (2) Date of 온라인 카지노 한국ntract 온라인 카지노 한국nclusion: |
11월 13, 2019 |
| (3) Scheduled Date of Share Transfer Execution
|
3월 1, 2020 (planned) |
Future Outlook
The impact on our group's 온라인 카지노 한국nsolidated performance for the fiscal year ending March 2020 is expected to be minimal. We will promptly announce any matters that should be disclosed in the future.